TG Therapeutics, Inc.
IT ˙ BIT ˙ US88322Q1085
34,00 € 0,00 (0,00%)
2026-06-05
DEL PRIS
SecurityIT:1TGTX / TG Therapeutics, Inc.
InstitutionCI Private Wealth, LLC
Latest Disclosed Ownership41,407 shares
Latest Disclosed Value $ 1,375,542
CI Private Wealth, LLC reports 0.85% decrease in ownership of 1TGTX / TG Therapeutics, Inc.

On May 15, 2026 - CI Private Wealth, LLC filed a 13F-HR form disclosing ownership of 41,407 shares of TG Therapeutics, Inc. (IT:1TGTX) valued at $1,145,318 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 9, 2026 disclosing 41,764 shares of TG Therapeutics, Inc.. This represents a change in shares of -0.85% during the quarter. The current value of the position is $1,407,838 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TG THERAPEUTICS COM 88322Q108 41,407 -357 -0.85 1,376 10.53 0.0019
2026-03-09 2025-12-31 13F/A-1 TG THERAPEUTICS COM 88322Q108 41,764 1,469 3.65 1,245 -14.50 0.0017
2026-02-19 2025-12-31 13F TG THERAPEUTICS COM 88322Q108 41,764 1,469 1,245 0.0005
2025-11-14 2025-09-30 13F TG THERAPEUTICS COM 88322Q108 40,295 -57 -0.14 1,456 0.21 0.0023
2025-09-26 2025-06-30 13F/A-1 TG THERAPEUTICS COM 88322Q108 40,352 -365 -0.90 1,452 -9.53 0.0019
2025-08-15 2025-06-30 13F TG THERAPEUTICS COM 88322Q108 80,704 39,987 2,905 0.0031
2025-05-14 2025-03-31 13F TG THERAPEUTICS COM 88322Q108 40,717 -6,661 -14.06 1,605 12.55 0.0026
2025-02-10 2024-12-31 13F TG THERAPEUTICS COM 88322Q108 47,378 -35,309 -42.70 1,426 -26.27 0.0024
2024-11-12 2024-09-30 13F TG THERAPEUTICS COM 88322Q108 82,687 -15,669 -15.93 1,934 10.58 0.0030
2024-08-13 2024-06-30 13F TG THERAPEUTICS COM 88322Q108 98,356 25,975 35.89 1,750 59.00 0.0030
2024-05-09 2024-03-31 13F TG THERAPEUTICS COM 88322Q108 72,381 -21,000 -22.49 1,101 -30.99 0.0020
2024-02-09 2023-12-31 13F TG THERAPEUTICS COM 88322Q108 93,381 65,220 231.60 1,595 578.30 0.0029
2023-11-03 2023-09-30 13F TG THERAPEUTICS COM 88322Q108 28,161 10,400 58.56 235 -46.71 0.0005
2023-08-10 2023-06-30 13F TG THERAPEUTICS COM 88322Q108 17,761 17,761 441 0.0010
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.